Earnings Preview: MCRB to Report Financial Results Pre-market on November 13
Press Release: Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024
This Verizon Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
J.P. Morgan Downgrades Seres Therapeutics(MCRB.US) to Sell Rating
Seres Cut to Underweight by JP Morgan on Vowst Sale
Seres Therapeutics Downgraded to Underweight From Neutral at JPMorgan
Seres Therapeutics Gains Amid Takeover Speculation
Seres Therapeutics Rumor Highlighted in Betaville Blog
Express News | Watching Seres Therapeutics; Traders Circulate M&A Blog Unconfirmed Rumor That Nestle Has Said To Have Made A Bid Between $6.90-$7.20/Share
Institutions Along With Retail Investors Who Hold Considerable Shares InSeres Therapeutics, Inc. (NASDAQ:MCRB) Come Under Pressure; Lose 12% of Holdings Value
Seres Therapeutics Files Registration for Resale of Shares by Societe Des Produits Nestle
Express News | Seres Therapeutics Files Prospectus Related to Resale,From Time to Time, of up to 14.3 Mln Shares of Common Stock by Selling Stockholder- SEC Filing
Express News | Mkt Capital: Request Seres Board Immediately Provide Stockholders With Facts for Its Engagement With Nestlé Ahead of Sept 30 Closing of Vowst Sale
Express News | Mkt Capital, Other Seres Therapeutics Stockholders: Express Concern on Report That Co Rebuffed Outright Takeover Offer From Nestlé
Express News | Seres Therapeutics Stockholders Issue Open Letter to Board of Directors Regarding Reported Engagement With Nestlé
Seres Therapeutics Stockholders Issue Open Letter to Board of Directors Regarding Reported Engagement With Nestlé
12 Health Care Stocks Moving In Thursday's After-Market Session
Seres Therapeutics Stockholders Approve Sale of VOWST to Nestlé Health Science; Sale Expected to Close on September 30
Express News | Seres Therapeutics Stockholders Approve Sale of Vowst™ to Nestlé Health Science; Sale Expected to Close on September 30
Seres Therapeutics Is Maintained at Buy by Canaccord Genuity
No Data
No Data